FY24 consensus $1.90. Raises FY24 revenue view to $2.75B-$2.825B from $2.78B-$2.8B, consensus $2.75B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
- Biomarin Pharmaceutical Inc. (BMRN) Q2 Earnings Cheat Sheet
- BioMarin announces FDA approval of sBLA for BRINEURA
- BioMarin price target raised to $115 from $111 at Wells Fargo
- BioMarin participates in a conference call with Jefferies